Label: REAPHIRM PLANT SOURCE DHA- prenatal supplement capsule, gelatin coated

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated November 28, 2011

If you are a consumer or patient please visit this version.

  • Contraindications

    Reaphirm Plant Source DHA is contraindicated in patients with hypersensitivity to any of its components or color additives.

    Folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid.

    Iron Therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron storage disease due to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc.), pyridoxine responsive anemia, or cirrhosis of the liver.

    Cyanocobalamin is contraindicated in patients with sensitivity to cobalt or to cyanocobalamin (Vitamin B12).

    Refer to MM1carton label


  • BOXED WARNING (What is this?)

    Boxed Warning

    WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6.  Keep this product out of the reach of children.  In case of accidental overdose, call a doctor or a Poison Control Center immediately.

  • WARNINGS/PRECAUTIONS:

    Reaphirm Plant Source DHA should be used with caution in patients with known sensitivity or allergy to soy.

    Vitamin D supplementation should be used with caution in those with hypercalcemia or conditions that may lead to hypercalcemia such as hyperparathyroidism and those who form calcium-containing kigney stones.  High doses of vitamin D can lead to elevated levels of calcium that reside in the blood and soft tissues.  Bone pain, high blood pressure, formation of kidney stones, renal failure, and increased risk of heart disease can occur.

    Iodine should be used with caution in patients with an overactive thyroid.

    Prolonged use of iron salts may produce iron storage disease.

    Folic acid, especially in doses above 0.1 mg daily, may obscure pernicious anemia, in that hematologic remission may occur while neurological manifestations remain progressive.

    The use of folic acid doses above 1 mg daily may precipitate or exacerbate the neurological damage of vitamin B12 deficiency.

    Consumption of more than 3 grams of omega-3 fatty acids per day from all sources may lead to excessive bleeding.  Supplemental intake of omega-3 fatty acids such as DHA exceeding 2 grams per day is not recommended.

    Avoid Overdosage.  Keep out of the reach of children.

    Drug Interactions:

    Medications for an overactive thyroid (anti-thyroid drugs) used in conjunction with iodine supplementation may lead to hypothyroidism.

    Medications for hypertension used in conjunction with iodine supplementation may increase potassium.

    High doses of folic acid may result in decreased serum levels of the anticonvulsant drugs.

    Vitamin D supplementation should not be given with large amounts of calcium in those with hypercalcemia or conditions that may lead to hypercalcemia such as hyperparathyroidism and those who form calcium-containing kidney stones.

    Zinc can inhibit the absorption of certain antibiotics; take at least 2 hours apart to minimize interactions.

    Consult appropriate references for additional specific vitamin-drug interactions.

    Information for Patients: Patients should be counseled to disclose all medical conditions, including use of all medications, vitamins and supplements, pregnancy, and breast-feeding.

    Pediatric Use: Not for pediatric use. 


    Adverse Reactions

    Adverse reactions have been reported with specific vitamins and minerals, but generally at doses substantially higher than those in Reaphirm Plant Source DHA.  Reported adverse events include skin ailments, gastrointestinal complaints, glucose abnormalities, and visual problems.

  • Dosage and Administration

    Before, during and after pregnancy, one softgel capsule daily, or as directed by a physician.

  • How Supplied

    Reaphirm Plant Source DHA is available as a dark blue, oval shaped softgel capsule imprinted "EV3010".  Available in Box of Unit-Dose pack of 30 (5 child resistant blister cards of 6 softgel capsules).

    Store at room temperature, approximately 15-30C (59-86F), avoid excessive heat.

    Rx Only

    Manufactured for

    EVERETT LABORATORIES, INC.


    West Orange, NJ 07052

    1-877-324-9349

  • Principal Display Panel

    reaphirm111128carton_lcr

    reaphirm111128carton_lcr
  • INGREDIENTS AND APPEARANCE
    REAPHIRM PLANT SOURCE DHA 
    prenatal supplement capsule, gelatin coated
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0642-3010
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Vitamin A (UNII: 81G40H8B0T) (Beta Carotene - UNII:01YAE03M7J) Beta Carotene1100 [iU]
    Ascorbic Acid (UNII: PQ6CK8PD0R) (Ascorbic Acid - UNII:PQ6CK8PD0R) Ascorbic Acid30 mg
    Thiamine Mononitrate (UNII: 8K0I04919X) (Thiamine - UNII:X66NSO3N35) Thiamine Mononitrate 1.6 mg
    Riboflavin (UNII: TLM2976OFR) (Riboflavin - UNII:TLM2976OFR) Riboflavin1.8 mg
    Niacin (UNII: 2679MF687A) (Niacinamide - UNII:25X51I8RD4) Niacinamide15 mg
    Pyridoxine Hydrochloride (UNII: 68Y4CF58BV) (Pyridoxine - UNII:KV2JZ1BI6Z) Pyridoxine2.5  mg
    Cyanocobalamin (UNII: P6YC3EG204) (Cyanocobalamin - UNII:P6YC3EG204) Cyanocobalamin.012 mg
    Folic Acid (UNII: 935E97BOY8) (Folic Acid - UNII:935E97BOY8) Folic Acid1 mg
    Iodine (UNII: 9679TC07X4) (Iodine - UNII:9679TC07X4) Iodine0.150 mg
    Magnesium (UNII: I38ZP9992A) (Magnesium Oxide - UNII:3A3U0GI71G) Magnesium Oxide20 mg
    Zinc (UNII: J41CSQ7QDS) (Zinc Oxide - UNII:SOI2LOH54Z) Zinc Oxide25 mg
    Copper (UNII: 789U1901C5) (Cupric Oxide - UNII:V1XJQ704R4) Cupric Oxide2 mg
    Vitamin D (UNII: 9VU1KI44GP) (Cholecalciferol - UNII:1C6V77QF41) Cholecalciferol1000 [iU]
    Omega-3 Fatty Acids (UNII: 71M78END5S) (Doconexent - UNII:ZAD9OKH9JC) Doconexent200 mg
    Vitamin E (UNII: H4N855PNZ1) (Alpha-Tocopherol - UNII:H4N855PNZ1) Alpha-Tocopherol20 [iU]
    Iron (UNII: E1UOL152H7) (Iron - UNII:E1UOL152H7) Iron29 mg
    Inactive Ingredients
    Ingredient NameStrength
    Gelatin (UNII: 2G86QN327L)  
    Sorbitol (UNII: 506T60A25R)  
    Glycerin (UNII: PDC6A3C0OX)  
    Soybean Oil (UNII: 241ATL177A)  
    Water (UNII: 059QF0KO0R)  
    Yellow Wax (UNII: 2ZA36H0S2V)  
    Anhydrous Dibasic Calcium Phosphate (UNII: L11K75P92J)  
    Lecithin, Soybean (UNII: 1DI56QDM62)  
    Titanium Dioxide (UNII: 15FIX9V2JP)  
    Sodium Thiosulfate (UNII: HX1032V43M)  
    Sunflower Oil (UNII: 3W1JG795YI)  
    Tocopherol (UNII: R0ZB2556P8)  
    Ascorbyl palmitate (UNII: QN83US2B0N)  
    Caramel (UNII: T9D99G2B1R)  
    FD&C Blue NO. 1 (UNII: H3R47K3TBD)  
    Corn Oil (UNII: 8470G57WFM)  
    Product Characteristics
    Colorblue (Dark Blue) Scoreno score
    ShapeOVAL (size 12 Oval Capsule) Size10mm
    FlavorImprint Code EV3010
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0642-3010-305 in 1 BOX
    16 in 1 BLISTER PACK
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other12/05/2011
    Labeler - Everett Laboratories, Inc. (071170534)
    Registrant - Everett Laboratories, Inc. (071170534)